Eli Lilly's obesity drug leadership faces a crucial test with the upcoming orforglipron launch. Our analysis examines whether the $800B valuation can withstand pricing pressures and manufacturing constraints. https://post.kapualabs.com/ye388vvf #PharmaAnalysis #Biotech #Investing $LLY